Copeptin as a biomarker for prediction of prognosis of acute ischemic stroke and transient ischemic attack: a meta-analysis

Article metrics

Abstract

This meta-analysis aimed to investigate the predictive effect of copeptin as a biomarker for the prognosis of acute ischemic stroke and transient ischemic attack. Electronic databases including PubMed, Medline, EMBASE, Web of Science and Cochrane Central were searched for studies assessing the association of copeptin level on admission with prognosis of acute ischemic stroke and transient ischemic attack. The Newcastle–Ottawa Quality assessment scale for cohort study was used to evaluate quality. A total of 1976 acute ischemic stroke patients from 6 studies were included, and 59% of patients were male. Patients with poor outcomes and nonsurvivors had a higher copeptin level at admission (P<0.0001). Copeptin combined with an admission National Institutes of Health Stroke Scale score significantly improved the discriminatory accuracy of functional outcome and mortality compared with the National Institutes of Health Stroke Scale alone. Elevation in plasma copeptin level carried a higher risk of all-cause mortality (odds ratio=4.16; 95% CI: 2.77–6.25) and poor functional outcome (odds ratio=2.56; 95% CI: 1.97–3.32) after acute ischemic stroke. In addition, copeptin improved the prognostic value of the ABCD2 (age, blood pressure, clinical features of transient ischemic attack, duration of symptoms and presence of diabetes mellitus) score for a recurrent cerebrovascular event in transient ischemic attack. Copeptin seems to be a promising independent biomarker for predicting the functional outcome and all-cause mortality within 3 months or 1 year after acute ischemic stroke, and it could also be a powerful tool for early risk stratification for patients with transient ischemic attack.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1
Figure 2
Figure 3
Figure 4

References

  1. 1

    Cheng XM, Ziegler DK, Lai YH, Li SC, Jiang GX, Du XL, Wang WZ, Wu SP, Bao SG, Bao QJ . Stroke in China, 1986 through 1990. Stroke 1995; 26: 1990–1994.

  2. 2

    Fukiyama K, Kimura Y, Wakugami K, Muratani H . Incidence and long-term prognosis of initial stroke and acute myocardial infarction in Okinawa, Japan. Hypertens Res 2000; 23: 127–135.

  3. 3

    Yang QD, Niu Q, Zhou YH, Liu YH, Xu HW, Gu WP, Tian FF, Xie YQ, Zhang L, Xia J . Incidence of cerebral hemorrhage in the Changsha community. A prospective study from 1986 to 2000. Cerebrovasc Dis 2004; 17: 303–313.

  4. 4

    Zhang JL, Yin CH, Zhang Y, Zhao LB, Fu HJ, Feng JC . Plasma copeptin and long-term outcomes in acute ischemic stroke. Acta Neurol Scand 2013; 128: 372–380.

  5. 5

    Zhang GH, He ML . Association between blood pressure variability and risk of stroke (Chinese). Chin J Neuromed 2014; 13: 749–752.

  6. 6

    Yong H, Foody J, Linong J, Dong Z, Wang Y, Ma L, Meng HJ, Shiff S, Dayi H . A systematic literature review of risk factors for stroke in China. Cardiol Rev 2013; 21: 77–93.

  7. 7

    De Marchis GM, Weck A, Audebert H, Benik S, Foerch C, Buhl D, Schuetz P, Jung S, Seiler M, Morgenthaler NG, Mattle HP, Mueller B, Christ-Crain M, Arnold M, Katan M . Copeptin for the prediction of recurrent cerebrovascular events after transient ischemic attack: results from the CoRisk study. Stroke 2014; 45: 2918–2923.

  8. 8

    Barreca T, Gandolfo C, Corsini G, Del Sette M, Cataldi A, Rolandi E, Franceschini R . Evaluation of the secretory pattern of plasma arginine vasopressin in stroke patients. Cerebrovasc Dis 2001; 11: 113–118.

  9. 9

    Baumann G, Dingman JF . Distribution, blood transport, and degradation of antidiuretic hormone in man. J Clin Invest 1976; 57: 1109–1116.

  10. 10

    Robertson GL, Mahr EA, Athar S, Sinha T . Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. J Clin Invest 1973; 52: 2340–2352.

  11. 11

    Preibisz JJ, Sealey JE, Laragh JH, Cody RJ, Weksler BB . Plasma and platelet vasopressin in essential hypertension and congestive heart failure. Hypertension 1983; 5 (2 Pt 2): I129–I138.

  12. 12

    Gunebakmaz O, Celik A, Inanc MT, Duran M, Karakaya E, Tulmac M, Akpek M, Sarli B, Ergin A, Topsakal R . Copeptin level and copeptin response to percutaneous balloon mitral valvuloplasty in mitral stenosis. Cardiology 2011; 120: 221–226.

  13. 13

    Morgenthaler NG, Struck J, Alonso C, Christ-Crain M, Müller B, Bergmann A . Measurement of the very stable vasopressin precursor copeptin as alternative to vasopressin in the clinical routine. Exp Clin Endocrinol Diabetes 2006; 114 (S1): P16_203.

  14. 14

    Morgenthaler NG, Struck J, Alonso C, Bergmann A . Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006; 52: 112–119.

  15. 15

    Johnston SC, Rothwell PM, Nguyen-Huynh MN, Giles MF, Elkins JS, Bernstein AL, Sidney S . Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet 2007; 369: 283–292.

  16. 16

    Purroy F, Jimenez Caballero PE, Gorospe A, Torres MJ, Alvarez-Sabin J, Santamarina E, Martinez-Sanchez P, Canovas D, Freijo MM, Egido JA, Giron JM, Ramirez-Moreno JM, Alonso A, Rodriguez-Campello A, Casado I, Delgado-Medeiros R, Marti-Fabregas J, Fuentes B, Silva Y, Quesada H, Cardona P, Morales A, de la Ossa N, Garcia-Pastor A, Arenillas JF, Segura T, Jimenez C, Masjuan J . Prediction of early stroke recurrence in transient ischemic attack patients from the PROMAPA study: a comparison of prognostic risk scores. Cerebrovasc Dis 2012; 33: 182–189.

  17. 17

    Hill MD . 2012 - Review: a dichotomized ABCD2 score has limited ability to predict stroke risk less than or equal to 90 days after TIA. ACP J Club 2013; 158: 1–1.

  18. 18

    Katan M, Fluri F, Morgenthaler NG, Schuetz P, Zweifel C, Bingisser R, Muller K, Meckel S, Gass A, Kappos L, Steck AJ, Engelter ST, Muller B, Christ-Crain M . Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol 2009; 66: 799–808.

  19. 19

    Katan M, Nigro N, Fluri F, Schuetz P, Morgenthaler NG, Jax F, Meckel S, Gass A, Bingisser R, Steck A, Kappos L, Engelter S, Muller B, Christ-Crain M . Stress hormones predict cerebrovascular re-events after transient ischemic attacks. Neurology 2011; 76: 563–566.

  20. 20

    Moher D, Liberati A, Tetzlaff J, Altman DG . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010; 8: 336–341.

  21. 21

    Wells G, Shea B, O'Connell D, Peterson D, Welch V, Losos M, Tugwell P . The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

  22. 22

    Higgins JP, Thompson SG, Deeks JJ, Altman DG . Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557–560.

  23. 23

    Begg CB, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088–1101.

  24. 24

    Egger M, Smith GD, Schneider M, Minder C . Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629–634.

  25. 25

    Dong X, Tao DB, Wang YX, Cao H, Xu YS, Wang QY . Plasma copeptin levels in Chinese patients with acute ischemic stroke: a preliminary study. Neurol Sci 2013; 34: 1591–1595.

  26. 26

    De Marchis GM, Katan M, Weck A, Fluri F, Foerch C, Findling O, Schuetz P, Buhl D, El-Koussy M, Gensicke H, Seiler M, Morgenthaler N, Mattle HP, Mueller B, Christ-Crain M, Arnold M . Copeptin adds prognostic information after ischemic stroke: results from the CoRisk study. Neurology 2013; 80: 1278–1286.

  27. 27

    Wang CW, Wang JL, Zhang Y, Li Q, Guo SX, Ji SB . Plasma levels of copeptin predict 1-year mortality in patients with acute ischemic stroke. Neuroreport 2014; 25: 1447–1452.

  28. 28

    Tu WJ, Dong X, Zhao SJ, Yang DG, Chen H . Prognostic value of plasma neuroendocrine biomarkers in patients with acute ischaemic stroke. J. Neuroendocrinol 2013; 25: 771–778.

  29. 29

    Purroy F, Suárez-Luis I, Cambray S, Farré J, Benabdelhak I, Mauri-Capdevila G, Sanahuja J, Quílez A, Begué R, Gil MI, Molina-Seguin J, Torreguitart N . The determination of copeptin levels helps management decisions among transient ischaemic attack patients. Acta Neurol Scand 2015; 134: 140–147.

  30. 30

    Katan M, Morgenthaler N, Widmer I, Puder JJ, Konig C, Muller B, Christ-Crain M . Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level. Neuro Endocrinol Lett 2008; 29: 341–346.

  31. 31

    Shuaib A, Xu Wang C, Yang T, Noor R . Effects of nonpeptide V(1) vasopressin receptor antagonist SR-49059 on infarction volume and recovery of function in a focal embolic stroke model. Stroke 2002; 33: 3033–3037.

  32. 32

    Dong X-Q, Yu W-H, Zhang Z-Y, Du Q, Yang D-B, Shen Y-F, Wang H, Zhu Q, Che Z-H, Liu Q-J . Comparison of the performances of copeptin and multiple biomarkers in long-term prognosis of severe traumatic brain injury. Peptides 2014; 60: 13–17.

  33. 33

    Morgenthaler NG, Muller B, Struck J, Bergmann A, Redl H, Christ-Crain M . Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock 2007; 28: 219–226.

  34. 34

    Zweifel C, Katan M, Schuetz P, Siegemund M, Morgenthaler NG, Merlo A, Mueller B, Christ-Crain M . Copeptin is associated with mortality and outcome in patients with acute intracerebral hemorrhage. BMC Neurol 2010; 10: 34.

  35. 35

    Pozsonyi Z, Forhecz Z, Gombos T, Karadi I, Janoskuti L, Prohaszka Z . Copeptin (C-terminal pro arginine-vasopressin) is an independent long-term prognostic marker in heart failure with reduced ejection fraction. Heart Lung Circ 2015; 24: 359–367.

  36. 36

    Lipinski MJ, Escarcega RO, D'Ascenzo F, Magalhaes MA, Baker NC, Torguson R, Chen F, Epstein SE, Miro O, Llorens P, Giannitsis E, Lotze U, Lefebvre S, Sebbane M, Cristol JP, Chenevier-Gobeaux C, Meune C, Eggers KM, Charpentier S, Twerenbold R, Mueller C, Biondi-Zoccai G, Waksman R . A systematic review and collaborative meta-analysis to determine the incremental value of copeptin for rapid rule-out of acute myocardial infarction. Am J Cardiol 2014; 113: 1581–1591.

  37. 37

    Zhang X, Lu XM, Huang LF, Ye H . Copeptin is associated with one-year mortality and functional outcome in patients with acute spontaneous basal ganglia hemorrhage. Peptides 2012; 33: 336–341.

  38. 38

    Ntaios G, Faouzi M, Ferrari J, Lang W, Vemmos K, Michel P . An integer-based score to predict functional outcome in acute ischemic stroke: the ASTRAL score. Neurology 2012; 78: 1916–1922.

  39. 39

    Strbian D, Seiffge DJ, Breuer L, Numminen H, Michel P, Meretoja A, Coote S, Bordet R, Obach V, Weder B . Validation of the DRAGON score in 12 stroke centers in anterior and posterior circulation. Stroke 2013; 44: 2718–2721.

  40. 40

    Koton S, Eizenberg Y, Tanne D, Grossman E . Trends in admission blood pressure and stroke outcome in patients with acute stroke and transient ischemic attack in a National Acute Stroke registry. J Hypertens 2016; 34: 316–322.

  41. 41

    Josephson SA, Hills NK, Johnston SC . NIH Stroke Scale reliability in ratings from a large sample of clinicians. Cerebrovasc Dis 2006; 22: 389–395.

  42. 42

    Sato S, Toyoda K, Uehara T, Toratani N, Yokota C, Moriwaki H, Naritomi H, Minematsu K . Baseline NIH Stroke Scale Score predicting outcome in anterior and posterior circulation strokes. Neurology 2008; 70: 2371–2377.

  43. 43

    Bustamante A, Garcia-Berrocoso T, Llombart V, Simats A, Giralt D, Montaner J . Neuroendocrine hormones as prognostic biomarkers in the setting of acute stroke: overcoming the major hurdles. Expert Rev Neurother 2014; 14: 1391–1403.

  44. 44

    Greisenegger S, Segal HC, Burgess AI, Poole DL, Mehta Z, Rothwell PM . Copeptin and long-term risk of recurrent vascular events after transient ischemic attack and ischemic stroke: population-based study. Stroke 2015; 46: 3117–3123.

Download references

Acknowledgements

We are deeply appreciative of the participants in this study and thank all staff for their support and assistance. This study was supported by the National Natural Science Foundation of China (Grant No. 81102189) and a Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions.

Author information

Correspondence to Hongmei Li.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Keywords

  • acute ischemic stroke
  • copeptin
  • prognosis
  • transient ischemic attack

Further reading